NEWS
TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery
TFF Pharmaceuticals (Nasdaq: TFFP) announces positive preclinical data published in the Journal of Drug Delivery Science and Technology, validating its Thin Film Freezing (TFF) technology as a superior approach for formulating dry powders for pulmonary drug delivery. The study compared TFF inhalational dry powders with jet-milling and spray-drying technologies in a rat model, demonstrating:
Enhanced uniform drug distribution in the lungs
Lower airway-to-lung distribution ratio
Rapid disaggregation of particles and subsequent movement of TFF nanoaggregates
TFF processed voriconazole dry powder showed the most homogeneous distribution in lung tissue, with the lowest airway-to-lung voriconazole deposition ratio (1.27) compared to spray-dried (1.76) and jet-milled (2.73) powders. These results suggest TFF inhalational dry powders may enhance treatment efficiency and reduce toxicity for lung diseases.
Enhanced uniform drug distribution in the lungs
Lower airway-to-lung distribution ratio
Rapid disaggregation of particles and subsequent movement of TFF nanoaggregates
TFF processed voriconazole dry powder showed the most homogeneous distribution in lung tissue, with the lowest airway-to-lung voriconazole deposition ratio (1.27) compared to spray-dried (1.76) and jet-milled (2.73) powders. These results suggest TFF inhalational dry powders may enhance treatment efficiency and reduce toxicity for lung diseases.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment